CNM-Au8 leads to clinical gains for RRMS patients in extension study
Daily treatment withĀ CNM-Au8 led to sustained improvements in vision and cognition for people with relapsing-remitting multiple sclerosis (RRMS), according to nearly three years of follow-up in the VISIONARY-MS trial and its open-label extension (OLE). Developer Clene Nanomedicine plans to present full trial results at the upcoming ACTRIMS…